In the ever-evolving landscape of HIV prevention, the recent WHO recommendation of injectable lenacapavir for HIV prevention has emerged as a revolutionary tool in the HIV Prevention toolkit.  The recommendation for the use of the twice a year injectable lenacapavir (LEN) as an additional option for pre-exposure prophylaxis for HIV prevention could transform how countries protect vulnerable populations. This biannual dosing schedule makes LEN a highly attractive option for individuals who struggle with daily adherence or face stigma around pill-taking.

LEN represents a bold leap forward in HIV prevention—offering discretion and effectiveness. The hope is that this innovation will empower more people to take control of their health and bring us closer to ending the HIV epidemic.

As countries gear up for its rollout, the South-South HIV Prevention Learning Network - Insight 2 Implementation, with input and review by the Clinton Health Access Initiative, the Global Fund to Fight AIDS, Tuberculosis and Malaria, and Wits RHI have developed a  Standard Operating Procedure for Injectable Lenacapavir as a Pre-exposure Prophylaxis  to provide an adaptable standard operating procedure (SOP) to support the development and adoption of national SOPs that align with World Health Organization (WHO) recommendations and guidance on injectable lenacapavir  (LEN) as pre-exposure prophylaxis (PrEP).

Designed as a template, this tool offers language and points for consideration for use by national policymakers during the creation or adaptation of national SOPs for LEN PrEP. The SOP includes prompts for national-level consideration during the adaptation process.

In addition, WHO and Jhpeigo also recently launched an online health provider e-training course for PrEP that includes LEN. This course will support providers with knowledge on how to offer multiple HIV PrEP methods.

These resources are also available on the South to South Learning Network.

‍